Keywords: Optimer Pharma, Fidaxomicin, EMEA, Seeks partner in Europe, Clostridium difficile

Optimer Pharma' fidaxomicin MA accepted for review by European Medicines Agency

Article | 20 August 2010

San Diego, USA-based Optimer Pharmaceuticals (Nasdaq; OPTR) said yesterday that the European Medicines Agency (EMEA) has accepted for review its ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Optimer Pharmaceuticals

Go to company listing